Sage's SAGE-217 meets in Phase II for MDD

Sage Therapeutics Inc. (NASDAQ:SAGE) said SAGE-217 met the primary endpoint in a double-blind, U.S. Phase II trial to treat moderate to severe major depressive disorder

Read the full 255 word article

User Sign In